Xianping Wu

Xianping Wu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2021 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
JWJun Wang
Jun Wang
FLFangchao Liu
Fangchao Liu
JLJianxin Li
Jianxin Li
KHKeyong Huang
Keyong Huang
XYXueli Yang
Xueli Yang
XLXiangfeng Lu
Xiangfeng Lu

1 October 2015 in Hypertension
Verified
Journal Article
Open access
PDF file
XLXiangfeng Lu
Xiangfeng Lu
JHJianfeng Huang
Jianfeng Huang
LWLaiyuan Wang
Laiyuan Wang
SCShufeng Chen
Shufeng Chen
XYXueli Yang
Xueli Yang
DGDongfeng Gu
Dongfeng Gu
Although multiple genetic markers associated with blood pressure have been identified by genome-wide association studies, their aggregate effect on risk of incident hypertension and cardiovascular disease is uncertain, particularly among East Asian who may have different genetic and environmental exposures from Europeans. We aimed to examine the association between genetic predisposition to higher blood pressure and risk of incident hypertension and cardiovascular disease in 26 262 individuals in 2 Chinese population-based prospective cohorts. A genetic risk score was calculated based on 22 established variants for blood pressure in East Asian. We found the genetic risk score was significantly and independently associated with linear increases in blood pressure and risk of incident hypertension and cardiovascular disease ( P range from 4.57×10 –3 to 3.10×10 –6 ). In analyses adjusted for traditional risk factors including blood pressure, individuals carrying most blood pressure–related risk alleles (top quintile of genetic score distribution) had 40% (95% confidence interval, 18–66) and 26% (6–45) increased risk for incident hypertension and cardiovascular disease, respectively, when compared with individuals in the bottom quintile. The genetic risk score also significantly improved discrimination for incident hypertension and cardiovascular disease and led to modest improvements in risk reclassification for cardiovascular disease (all the P <0.05). Our data indicate that genetic predisposition to higher blood pressure is an independent risk factor for blood pressure increase and incident hypertension and cardiovascular disease and provides modest incremental information to cardiovascular disease risk prediction. The potential clinical use of this panel of blood pressure–associated polymorphisms remains to be determined.

3 December 2024 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
HPHaobin Peng
Haobin Peng
JWJiajun Wen
Jiajun Wen
MCManli Chen
Manli Chen
ZXZhengyuan Xia
Zhengyuan Xia
YJYing Jiang
Ying Jiang
XWXianping Wu
Xianping Wu
Introduction Single-injection pericapsular nerve group (PENG) block with ropivacaine provides clear analgesic effects in preoperative pain management for hip fractures. However, it suffers from insufficient duration, failing to meet the needs of most patients. This single-center, randomized controlled, observer-blinded trial utilizes a novel combination of liposomal bupivacaine (LB) single-injection PENG block to examine its efficacy, duration, and safety in preoperative analgesia for hip fractures, aiming to develop a new preoperative analgesic protocol. Methods Sixty-six patients with hip fractures received ultrasound-guided single-injection PENG block with LB or ropivacaine after admission. The primary outcome was the static and dynamic pain scores measured at 48 h post-block. Pain scores at 12, 24, 36, 60, and 72 h post-block, rescue analgesia rate, time to first opioid, additional morphine consumption, and adverse events were assessed as the secondary outcomes. Results LB versus ropivacaine group at 48 h post-block, with a median interquartile range (IQR) of 2 (1.0–2.0) versus 3 (2.0–3.0) at static pain score and 2 (1.75–3.0) versus 4 (4.0–5.0) at dynamic pain score. LB group had lower dynamic and static pain scores at other observation points except for the static pain score at 72 h, lower pain intensity [sum of pain intensity difference (SPID)0–24, SPID0–48 and SPID0–72], longer time to first opioid, lower additional morphine consumption, and lower incidence of nausea and vomiting. No significant inter-group differences were detected in other secondary outcomes. Conclusions For preoperative analgesia of hip fractures, LB single-injection PENG block had a similar analgesic intensity and safety as ropivacaine but provided a longer duration of analgesia, reaching 48 h and even extending beyond 60 h, which reduced opioid consumption and extended time to the first opioid. Trial Registration The protocol was registered in www.chictr.org.cn under the identifier ChiCTR2300072939.

22 November 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
JZJianyu Zhu
Jianyu Zhu
JCJiahao Chen
Jiahao Chen
YZYuefen Zuo
Yuefen Zuo
KSKun Song
Kun Song
HLHuilian Liao
Huilian Liao
XWXianping Wu
Xianping Wu
Background: Common side effect of Herpes Zoster, postherpetic neuralgia (PHN), causes persistent pain that seriously affects quality of life. Lack of dependable biomarkers makes the clinical diagnosis and treatment of PHN difficult, so complicating the assessment of therapeutic efficacy. Blood metabolites are becoming more and more well known as significant disease markers. With an aim to find possible biomarkers for diagnosis and treatment, this work investigates the causal link between blood metabolites and PHN using Mendelian randomization.Methods: This work evaluated causal relationships between PHN and 1,091 plasma metabolites using Mendelian randomization (MR). Complementing MR-Egger and weighted median approaches, the main causality analysis was done using inverse variance weighted (IVW) and Wald ratio (WR) approaches. Robustness was checked using sensitivity analyses including CAUSE, Cochran’s Q tests, leave-one-out analysis, MR-PRESSO, and MR-Egger intercept analysis. Reverse MR analysis and linkage disequilibrium score regression (LDSC) was used to assess significant correlations as well. Two-step MR analysis was also used to look at the mediating function of positively correlated metabolites in the causal pathway.Results: The results of this study indicated a significant association between N-acetyl-aspartyl-glutamate (NAAG) and PHN, with an odds ratio (OR) of 0.83 (95% CI: 0.76–0.91, p = 2.68E-05). Moreover, five potential associated metabolites were identified: Gamma-glutamylthreonine (OR = 1.60, 95% CI: 1.16–2.20, p = 0.004), 3-hydroxyphenylacetoylglutamine (OR = 1.43, 95% CI: 1.00–2.05, p = 0.048), Caprate (10:0) (OR = 1.86, 95% CI: 1.11–3.12, p = 0.018), X-12013 (OR = 1.64, 95% CI: 1.03–2.60, p = 0.035), and X-17328 (OR = 1.50, 95% CI: 1.04–2.18, p = 0.032). Additionally, NAAG likely acts as a complete mediator between FOLH1(CGPII) and postherpetic neuralgia in the causal pathway.Conclusion: The results of this study indicated a significant association between N-acetyl-aspartyl-glutamate (NAAG) and PHN, with an odds ratio (OR) of 0.83 (95% CI: 0.76–0.91, p = 2.68E-05). Furthermore five possible related metabolites were found: Glutamylthreonine gamma-wise (OR = 1.60, 95% CI: 1.16–2.20, p = 0.004), 3-hydroxyphenylacetoylglutamine (OR = 1.43, 95% CI: 1.00–2.05, p = 0.048), Caprate (10:0) (OR = 1.86, 95% CI: 1.11–3.12, p = 0.018), X-12013 (OR = 1.64, 95% CI: 1.03–2.60, p = 0.035), and X-17328 (OR = 1.50, 95% CI: 1.04–2.18, p = 0.032). Furthermore, in the causal pathway NAAG most certainly serves as a complete mediator between FOLH1(CGPII) and postherpetic neuralgia.

1 July 2026 in Annals of Medicine
Verified
Journal Article
Open access
HPHaobin Peng
Haobin Peng
JWJiajun Wen
Jiajun Wen
YJYing Jiang
Ying Jiang
JOJianxin Ou
Jianxin Ou
XWXianping Wu
Xianping Wu
MCManli Chen
Manli Chen
Transcutaneous auricular vagus nerve stimulation (taVNS) provides targeted modulation of the autonomic nervous system and descending pain pathways, exerting analgesic potential. However, high-quality evidence remains insufficient to determine whether taVNS can effectively replace opioids in sedation regimens for same-session bidirectional endoscopy while maintaining the quality of early postoperative recovery. This study is a single-center, prospective, randomized, double-blind, placebo-controlled, three-arm non-inferiority trial. A total of 181 patients scheduled for painless same-session bidirectional endoscopy will be enrolled and randomly assigned using dynamic block randomization to one of three groups: Group S (sufentanil 0.1 µg/kg plus sham taVNS), Group T (normal saline plus active taVNS), and Group P (normal saline plus sham taVNS). All participants will receive ciprofol for sedation induction and maintenance. The primary outcome will be the quality of recovery at 24 h postoperatively, assessed using the 15-item Quality of Recovery scale (QoR-15), with a predefined non-inferiority margin (δ) of 6 points, which corresponds to the minimal clinically important difference of the QoR-15 scale. Secondary outcomes will include perioperative adverse events (pre-, intra-, and postoperative, including taVNS-related events), QoR-15 score at 1 h postoperatively, procedural and recovery efficiency indices, sedative dosage, and patient and endoscopist satisfaction scores. Blinding effectiveness will be assessed in all participants, and statistical analyses will follow the modified intention-to-treat principle. This study protocol will rigorously assess the effectiveness and safety of taVNS as an alternative to opioid analgesics for sedation during same-session bidirectional endoscopy using, to our knowledge, the first three-arm design.Trial registration: Chinese Clinical Trial Registry (ChiCTR2600117962).

15 May 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
JZJianyu Zhu
Jianyu Zhu
YWYixuan Wang
Yixuan Wang
GYGuangchao Yu
Guangchao Yu
LLLin Li
Lin Li
JHJinyong He
Jinyong He
XWXianping Wu
Xianping Wu
Background: The Metabolic Score for Visceral Fat (METS-VF) offers a refined measure of visceral adiposity, potentially surpassing traditional metrics. This study examines the association between METS-VF and chronic pain in U.S. adults.Methods: We analyzed data from 5,905 adults aged 18 years and older from the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Weighted multivariate linear regression and restricted cubic spline analyses were conducted to investigate the linear associations between METS-VF and chronic pain. Threshold effects were determined using a two-part linear regression model. Subgroup analyses were conducted across three age groups (18–39, 40–64, and ≥65 years). The predictive accuracy of METS-VF, body mass index (BMI), and waist circumference (WC) was evaluated using ROC curve analysis. Influential predictors of chronic pain were identified via XGBoost, and mediation analysis assessed the role of C-reactive protein (CRP).Results: Among participants (mean age, 46.8 years; 50.8% female), chronic pain prevalence was 14.6%. Higher METS-VF was associated with increased odds of chronic pain (adjusted OR per unit increase, 1.46; 95% CI, 1.13–1.87), with a threshold effect at METS-VF 5.714. The highest METS-VF quartile showed greater odds of chronic pain (OR, 1.87; 95% CI, 1.28–2.72; P for trend = 0.003). In adults ≥65 years, METS-VF demonstrated superior discrimination (AUC, 0.618) compared to BMI and waist circumference. XGBoost identified METS-VF as the most influential predictor, with CRP partially mediating the association (7.4% of total effect; p = 0.01).Conclusion: METS-VF independently associated with higher odds of chronic pain, especially in older adults.